Search results for "apolipoprotein"

showing 10 items of 354 documents

Controlling protein interactions in blood for effective liver immunosuppressive therapy by silica nanocapsules

2020

Immunosuppression with glucocorticoids is a common treatment for autoimmune liver diseases and after liver transplant, which is however associated with severe side-effects. Targeted delivery of glucocorticoids to inflammatory cells, e.g. liver macrophages and Kupffer cells, is a promising approach for minimizing side effects. Herein, we prepare core–shell silica nanocapsules (SiO2 NCs) via a sol–gel process confined in nanodroplets for targeted delivery of dexamethasone (DXM) for liver immunosuppressive therapy. DXM with concentrations up to 100 mg mL−1 in olive oil are encapsulated while encapsulation efficiency remains over 95% after 15 days. Internalization of NCs by non-parenchymal muri…

Apolipoprotein BCell SurvivalLiver cytologyPharmacologybehavioral disciplines and activitiesDexamethasoneNanocapsulesProinflammatory cytokine//purl.org/becyt/ford/1 [https]MiceDrug Delivery SystemsDrug StabilityNanocapsulesQuímica Coloidalmental disordersBlood plasma//purl.org/becyt/ford/1.4 [https]AnimalsHumansIMMUNOSUPPRESSIVE THERAPYTissue DistributionGeneral Materials ScienceColloidsImmunosuppression TherapybiologyClusterinChemistryCiencias QuímicasSILICA NANOCAPSULESSilicon DioxideBlood proteinsPROTEIN INTERACTIONSDEXAMETHASONELiverbiology.proteinPEGylationCytokinesCIENCIAS NATURALES Y EXACTASImmunosuppressive AgentsHeLa CellsNanoscale
researchProduct

The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation …

1992

A previous study has shown that complement component C3 binds to recombinant apolipoprotein(a) (r-apo(a)). In the present report we have investigated the interactions between lipoprotein(a) (Lp(a)), r-apo(a) and C3 in relation to complement activation and degradation. Neither Lp(a) nor r-apo(a) affected complement activation as indicated by sheep and rabbit red blood cell hemolytic assays, and by assessment of the amount of C3a generated in zymosan-activated human serum in the presence or absence of Lp(a). Crossed immunoelectrophoretic analyses indicated that Lp(a) retarded the migration of iC3b in complement-activated serum but had no effects on C3, C3b, C3c or C3dg. Recombinant apo(a) exh…

Apolipoprotein BLipoproteinsApoprotein(a)chemistry.chemical_compoundHumansComplement ActivationbiologyComplement C3Lipoprotein(a)N-Acetylneuraminic AcidComplement systemSialic acidApolipoproteinsBiochemistrychemistryLow-density lipoproteinComplement C3bSialic Acidsbiology.proteiniC3bElectrophoresis Polyacrylamide Gellipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineImmunoelectrophoresis Two-DimensionalN-Acetylneuraminic acidLipoprotein(a)LipoproteinAtherosclerosis
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

2020

Several lines of evidence now attest that lipoprotein[a] (Lp[a]) is a significant risk factor for many cardiovascular disorders. This enigmatic lipoprotein, composed of a single copy of apolipoprotein B (apoB) and apolipoprotein[a] (apo [a]), expresses peculiar metabolism, virtually independent from lifestyle interventions. Several therapeutic options have hence been proposed for lowering elevated Lp[a] values, with or without concomitant effect on low density lipoprotein (LDL) particles, mostly encompassing statins, ezetimibe, nicotinic acid, lipoprotein apheresis, and anti-PCSK9 monoclonal antibodies. Since all these medical treatments have some technical and clinical drawbacks, a novel s…

Apolipoprotein Bmedicine.drug_classgovernment.form_of_governmentAntisense therapyHyperlipidemias030204 cardiovascular system & hematologyPharmacologyAntisense therapy; Apolipoprotein[a]; Cardiovascular disease; Lipoprotein[a]Monoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeLipoprotein[a]Internal MedicinemedicineHumans030212 general & internal medicineAntisense therapybiologybusiness.industryLipoprotein(a)Cardiovascular diseaseLipoproteins LDLchemistryConcomitantLow-density lipoproteinBlood Component Removalbiology.proteingovernmentlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein[a]Lipoprotein(a)Lipoproteinmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Reductive stress in young healthy individuals at risk of Alzheimer disease.

2013

Oxidative stress is a hallmark of Alzheimer disease (AD) but this has not been studied in young healthy persons at risk of the disease. Carrying an Apo e4 allele is the major genetic risk factor for AD. We have observed that lymphocytes from young, healthy persons carrying at least one Apo e4 allele suffer from reductive rather than oxidative stress, i.e., lower oxidized glutathione and P-p38 levels and higher expression of enzymes involved in antioxidant defense, such as glutamylcysteinyl ligase and glutathione peroxidase. In contrast, in the full-blown disease, the situation is reversed and oxidative stress occurs, probably because of the exhaustion of the antioxidant mechanisms just ment…

Apolipoprotein EAdultMaleAntioxidantGenotypemedicine.medical_treatmentApolipoprotein E4DiseaseBiologymedicine.disease_causeBiochemistryAntioxidantschemistry.chemical_compoundAlzheimer DiseaseRisk FactorsPhysiology (medical)medicineHumansAlleleAlleleschemistry.chemical_classificationGlutathione PeroxidaseGlutathione peroxidaseGlutathioneMiddle Agedmedicine.diseaseGlutathioneOxidative StresschemistryImmunologyFemaleLipid PeroxidationAlzheimer's diseaseOxidative stressBiomarkersFree radical biologymedicine
researchProduct

Lymphocytes from young healthy persons carrying the ApoE4 allele overexpress stress-related proteins involved in the pathophysiology of Alzheimer's d…

2012

Abstract Apolipoprotein E4 (ApoE4) is a major genetic risk factor for the development of Alzheimer's disease (AD). The aim of this work was to find if carrying ApoE4 alleles correlates with molecular changes associated with specific processes involved in AD pathophysiology and whether they are useful as early biomarkers of AD. Fifty four young healthy adults (aged 20-55) were recruited. Of these, 33 carried at least one ApoE4 allele and 21 did not (ApoE 3/3). We also recruited eleven patients with clinical diagnoses of probable AD and nine persons of similar age without dementia who served as controls of the AD patients. Using peripheral lymphocytes, we measured RNA expression of glycogen s…

Apolipoprotein EAdultMaleApolipoprotein E4BiologyYoung AdultGSK-3Alzheimer DiseaseGenotypemedicineDementiaHumansLymphocytesAlleleAllelesHeat-Shock ProteinsAgedAged 80 and overGeneral NeuroscienceGenetic Carrier ScreeningGeneral MedicineMiddle Agedmedicine.diseaseProtein kinase RPathophysiologyCalcineurinPsychiatry and Mental healthClinical PsychologyGene Expression RegulationImmunologyFemaleGeriatrics and GerontologyJournal of Alzheimer's disease : JAD
researchProduct

Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy.

2003

There is interest in the role of iron in age-related diseases such as atherosclerosis. Tissue iron deposition could be harmful, because Fe(2+) can react with H(2)O(2) to form OH(-) radicals and Fe(2+) can react with O(2) to form reactive oxygen species. Free radicals react with cell membranes and cell organelles and could lead to the development of atherosclerosis by initiating lipid peroxidation. Hereditary hemochromatosis provides an opportunity for studying the effects of iron on cardiovascular disease. Some studies have shown that individuals who carried HFE mutations may be at greater risk of developing coronary heart disease than those without the mutations. In contrast, a large numbe…

Apolipoprotein EAdultMalePathologymedicine.medical_specialtySettore MED/09 - Medicina InternaGenotypePopulationApolipoprotein E4Mutation MissenseMyocardial InfarctionPhysiologyApolipoproteins EGene FrequencyGenotypeMedicineHumansAge FactorMyocardial infarctionAlleleeducationHemochromatosis ProteinMembrane ProteinMolecular BiologyAllele frequencyAgedAged 80 and overeducation.field_of_studybusiness.industryHistocompatibility Antigens Class ICase-control studyAge FactorsMembrane ProteinsCell BiologyHematologyMiddle Agedmedicine.diseaseItalyHereditary hemochromatosisCase-Control StudiesMolecular MedicineFemaleCase-Control StudiebusinessHumanBlood cells, moleculesdiseases
researchProduct

Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer's disease as shown by partially overlapping of gene variant profile…

2011

Abstract Gene variants that promote inflammation and cholesterol metabolism have been associated with acute myocardial infarction (AMI) and Alzheimer's disease (AD). We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD: IL10 -1082G/A, IL6 -174G/C, TNF -308G/A, IFNG +874T/A, SERPINA3 -51G/T, HMGCR -911C/A, APOE e2/3/4 (280 AMI cases, 257 AD cases, and 1307 population controls, all Italian (presumed risk alleles are shown in bold). Six genetic risk sets I to VI were identified by fuzzy latent classification: I had low risk; II and III had low risk before age 65 (II, III); low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE. Pro-infla…

Apolipoprotein EAdultMalePopulationMyocardial InfarctionDiseaseAlzheimer DiseaseRisk FactorsGenes OverlappingMedicineHumansSettore MED/05 - Patologia ClinicaGenetic Predisposition to DiseaseMyocardial infarctionAlleleeducationgenetic risk markers common soil alzheimer disease AMI GOM analysysGeneAgedGeneticsAged 80 and overeducation.field_of_studybusiness.industryGeneral NeuroscienceGene Expression ProfilingGenetic VariationGeneral MedicineMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologyRelative riskImmunologyTumor necrosis factor alphaFemaleGeriatrics and Gerontologybusiness
researchProduct

The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European p…

2005

Abstract Background Apolipoprotein E (ApoE) locus has consistently shown a significant association with low-density lipoprotein cholesterol (LDL-C). However, its impact on high-density lipoprotein cholesterol (HDL-C) has been highly controversial suggesting that it may be context-dependent. We examined the gene–gene interaction between the common ApoE and the CETP polymorphisms in determining HDL-C concentrations in men and women from the general population. Methods 550 unrelated Caucasian subjects were randomly selected from a Mediterranean Region in Spain. Plasma lipids, anthropometric, clinical and lifestyle variables were measured. Common ApoE and CETP-TaqIB polymorphisms were determine…

Apolipoprotein EAdultMalemedicine.medical_specialtyAdolescentGenotypeClinical BiochemistryPopulationPhysical exerciseLocus (genetics)BiologyBiochemistryWhite PeopleApolipoproteins EGene FrequencyInternal medicineGenotypeCholesterylester transfer proteinmedicineHumansAlleleeducationAllelesAgedGlycoproteinsGeneticsAged 80 and overeducation.field_of_studyPolymorphism GeneticModels GeneticBiochemistry (medical)Cholesterol HDLGenetic VariationGeneral MedicineMiddle AgedLipidsCholesterol Ester Transfer ProteinsEndocrinologySpainbiology.proteinlipids (amino acids peptides and proteins)FemaleCarrier ProteinsBody mass indexClinica chimica acta; international journal of clinical chemistry
researchProduct